Rocket Pharmaceuticals Files 8-K: Other Events

TL;DR

Rocket Pharma filed an 8-K for 'Other Events' on Oct 3rd - details TBD.

AI Summary

Rocket Pharmaceuticals, Inc. filed an 8-K on October 3, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself. The company's principal executive offices are located at 350 Fifth Avenue, Suite 7530, New York, NY 10118.

Why It Matters

This filing indicates that Rocket Pharmaceuticals has reported significant events to the SEC, but the lack of detail requires further investigation to understand the implications for the company.

Risk Assessment

Risk Level: medium — The filing is an 8-K for 'Other Events' without specific details, which could range from minor administrative changes to significant undisclosed corporate actions.

Key Players & Entities

• ROCKET PHARMACEUTICALS, INC. (company) — Registrant
• October 3, 2025 (date) — Filing Date
• 350 FIFTH AVENUE, SUITE 7530, NEW YORK, NY 10118 (location) — Principal Executive Offices
• INOTEK PHARMACEUTICALS CORP (company) — Former Company Name

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common stock, $0.01 par value RCKT The Nasdaq Global Ma

Filing Documents

• ef20056613_8k.htm (8-K) — 29KB
• 0001140361-25-037163.txt ( ) — 154KB
• rckt-20251003.xsd (EX-101.SCH) — 4KB
• rckt-20251003_lab.xml (EX-101.LAB) — 21KB
• rckt-20251003_pre.xml (EX-101.PRE) — 16KB
• ef20056613_8k_htm.xml (XML) — 4KB

01

Item 8.01. Other Events. On October 3, 2025, Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") reported that it has voluntarily withdrawn its Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for mozafancogene autotemcel (also known as "Fanskya," "Fanca-cel," or "RP-L102"), an investigational gene therapy for the treatment of Fanconi Anemia ("FA"). This decision follows the Company's previously announced corporate prioritization, under which Rocket is focusing its resources on programs with the clearest regulatory and commercial pathways. As a result, Rocket ceased new internal investment in RP-L102 in July 2025, subsequently withdrew its Marketing Authorization Application ("MAA") with the European Medicines Agency in July 2025, and has now withdrawn its U.S. BLA. The Company's decision to withdraw the BLA is based on business and strategic considerations and does not reflect concerns regarding the safety or efficacy profile of RP-L102. Data generated to date continue to support that RP-L102 has been generally well tolerated, with no significant safety signals observed, and a risk-benefit profile that appears favorable. The Company will consider external partnership opportunities that could potentially enable the advancement of RP-L102 in the future. Withdrawal of the BLA preserves Rocket's ability to re-engage with regulators at a later date should there be an appropriate strategic or partnership pathway to sustainably progress the program

Forward-Looking Statements

Forward-Looking Statements Except for the factual statements made herein, information contained in this Current Report on Form 8-K consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects or future events, as well as words such as "believes," "intends," "expects," "plans" and similar expressions, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. For example, there can be no assurance that the Company will enter into any external new partnerships that enable the advancement of RP-L102. Reference is also made to other factors detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. The forward-looking statements contained in this Current Report on Form 8-K speak only as of the date of this Current Report on Form 8-K and the Company assumes no obligation to publicly update any forward-looking statements to reflect changes in information, events or circumstances after the date of this Current Report on Form 8-K, unless required by law.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Rocket Pharmaceuticals, Inc. Date: October 3, 2025 By: /s/ Martin Wilson Martin Wilson General Counsel and Chief Corporate Officer, SVP

View Full Filing

View this 8-K filing on SEC EDGAR